Zoetis Inc. (NYSE:ZTS) Shares Sold by Moseley Investment Management Inc.

Moseley Investment Management Inc. reduced its stake in Zoetis Inc. (NYSE:ZTS) by 23.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 5,642 shares of the company’s stock after selling 1,767 shares during the quarter. Moseley Investment Management Inc.’s holdings in Zoetis were worth $919,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Darwin Wealth Management LLC purchased a new stake in Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis in the 3rd quarter valued at $33,000. Dunhill Financial LLC lifted its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Quarry LP lifted its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $164.31 on Wednesday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market cap of $74.13 billion, a P/E ratio of 30.89, a PEG ratio of 2.91 and a beta of 0.89. The firm has a fifty day moving average price of $171.31 and a 200 day moving average price of $180.16.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.36 earnings per share. Sell-side analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is currently 37.59%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.